Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected ...

Novavax (NASDAQ:NVAX) shares lost ~12% in the premarket on Tuesday after the Gaithersburg, MD-based biotech, with its Q3 2024 ...

On NVAX's third-quarter earnings call, investors will likely seek updates on management???s ongoing discussions with the FDA ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Analysts are estimating that Novavax will report an earnings per share (EPS) of $-0.87. Anticipation surrounds Novavax's ...

Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...

Good morning and welcome to Novavax' Third Quarter 2024 Financial Results and Operational Highlights Conference Call. All ...

Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

The Food and Drug Administration has cleared Novavax to move forward with testing of a combination vaccine for COVID-19 and ...

The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...